Xanax (Alprazolam) Onsite Taper

No, and you should not attempt it on your own. You arrive on your current prescribed alprazolam dose. Stopping a benzodiazepine abruptly without supervision is genuinely dangerous, which is precisely why the reduction is done onsite: cross-titration to diazepam (or clonazepam) using Ashton-method equivalents BEFORE the iboga component. A small number of other medications (MAOIs, lithium, tricyclic antidepressants, tramadol and certain QT-prolonging cardiac medications) do still need to be cleared before you arrive, so our medical team reviews your full medication list in advance.

Typically 21-60 days onsite (longest of any class, driven by seizure-safety floor). That range is driven by alprazolam's short half-life (≈ 11 hours) and your baseline dose, usually 0.25-4 mg/day (medical), higher in tolerant users. Reductions are hyperbolic rather than linear, so the schedule follows how you actually respond instead of running to a fixed calendar.

The alprazolam discontinuation profile covers: Seizure risk (highest of the benzodiazepine class); Severe rebound anxiety and panic; Insomnia, derealization, depersonalization; Tremor, sweating, autonomic instability; Tinnitus, sensory hypersensitivity; Protracted withdrawal syndrome possible. The onsite protocol bridges the taper with sub-psychoactive iboga total alkaloid (50-150 mg BID) to cover the receptor-occupancy gap as your dose comes down, with symptom-driven support and continuous monitoring throughout.

Alprazolam has the steepest tolerance curve of any benzodiazepine. Seizure risk on abrupt cessation makes home tapers genuinely dangerous. The Ashton method calls for cross-titration to diazepam first. Most physicians won't manage this outpatient. Protracted withdrawal can persist for months without supervised support.

Yes. Cross-titration to diazepam (or clonazepam) using Ashton-method equivalents BEFORE the iboga component. Hyperbolic diazepam taper of 5-10% every 7-14 days. Iboga TA bridge 50-150 mg BID covers GABAergic rebound and protracted-withdrawal symptoms. Continuous cardiac telemetry + EEG monitoring at the highest-risk taper steps. Seizure-prophylactic dosing of magnesium and electrolyte normalization.

A flood dose of ibogaine HCl is only administered once alprazolam has been reduced to a protocol-defined safe threshold and your cardiac screening is still within limits. Eligibility is confirmed at that point rather than promised in advance. Ibogaine is an investigational compound, is not approved by the FDA, and results vary between patients. If your medication picture or your screening makes treatment unsafe, we will tell you honestly.